Anika Therapeutics
ANIK
194 hedge funds and large institutions have $761M invested in Anika Therapeutics in 2019 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 58 increasing their positions, 70 reducing their positions, and 12 closing their positions.
242% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 12
33% more capital invested
Capital invested by funds: $574M → $761M (+$187M)
18% more funds holding
Funds holding: 165 → 194 (+29)
1.2% more ownership
Funds ownership: 99.46% → 100.66% (+1.2%)
17% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 70
92% less call options, than puts
Call options by funds: $2.37M | Put options by funds: $29.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$10.1M |
| 2 |
MCM
Matarin Capital Management
New York
|
+$8.21M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$7.98M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$6.41M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$4.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$18.3M |
| 2 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$14.6M |
| 3 |
Two Sigma Investments
New York
|
-$6.16M |
| 4 |
Millennium Management
New York
|
-$4.97M |
| 5 |
BlackRock
New York
|
-$3.73M |
ANIK Hedge Fund Activity: Q3 2019 in Review
194 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2019, worth a combined $761M — up 33% from $574M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ANIK positions and 12 closed out — a net gain of 29 holders — while 58 added to existing stakes and 70 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $10.1M. The largest seller was Ameriprise, cutting an estimated $18.3M.
- 194 institutional investors held Anika Therapeutics (ANIK) as of Q3 2019, up from 165 in Q2 2019.
- Funds reported $761M of Anika Therapeutics stock for Q3 2019, up 33% quarter-over-quarter.
- 41 funds opened new Anika Therapeutics positions in Q3 2019 and 12 closed out, a net change of +29 holders.
- The largest Anika Therapeutics buyer in Q3 2019 was Acadian Asset Management, an estimated $10.1M added.
- The largest Anika Therapeutics seller in Q3 2019 was Ameriprise, an estimated $18.3M sold.
Based on aggregated 13F filings for Q3 2019.